ScripsAmerica secures $1 million in financing for RapiMed launch

NEW CASTLE, Del. — ScripsAmerica last week announced that the company has secured $1 million in financing, which it will use to develop, manufacture and distribute its RapiMed brand of children's pain reliever and other core business products.

"ScripsAmerica is very pleased to secure the funding necessary to ensure a successful product launch of RapiMed, currently slated for the first quarter of next year," stated Bob Schneiderman, ScripsAmerica CEO. "The company can now implement the most effective strategies for the development, manufacturing and marketing of RapiMed leading up to the launch without cash constraints, enabling us to grow faster and focus on meeting market demand."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.